Zacks.com on MSN3d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
Investor's Business Daily on MSN17d
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a six-month study.
Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...
The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...
A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors. The biotech ...
Analyst Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at $38.00. Discover outperforming stocks and ...
In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...
Baird last night initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating and $31 price target The firm believes Denali is likely to establish itself as a commercial company in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback